JOP20200002A1 - شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري - Google Patents

شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري

Info

Publication number
JOP20200002A1
JOP20200002A1 JOP/2020/0002A JOP20200002A JOP20200002A1 JO P20200002 A1 JOP20200002 A1 JO P20200002A1 JO P20200002 A JOP20200002 A JO P20200002A JO P20200002 A1 JOP20200002 A1 JO P20200002A1
Authority
JO
Jordan
Prior art keywords
fab fragment
cancer
human ceacam5
antibody fab
ceacam5 antibody
Prior art date
Application number
JOP/2020/0002A
Other languages
English (en)
Inventor
Kazunori Hirayama
Hiroki Shirai
Hitoshi Doihara
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JOP20200002A1 publication Critical patent/JOP20200002A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري الملخص يزود هذا الاختراع شدفة Fab لجسم مضاد ضد CEACAM5 بشري من المتوقع أن تكون مفيدة في تشخيص السرطان، وخاصة تشخيص سرطان القولون والمستقيم، سرطان الثدي، سرطان الرئة، سرطان الغدة الدرقية، أو سرطان ناتج عن نقائلها وطريقة تشخيص باستخدام متقارن يشتمل على شدفة Fab. ويزود الاختراع الحالي شدفة Fab لجسم مضاد ضد CEACAM5 بشري تشتمل على شدفة ذات سلسلة ثقيلة تشتمل على منطقة متغيرة لسلسلة ثقيلة تتكون من سياق الأحماض الأمينية الذي تمثله مواقع الأحماض الأمينية من 1 إلى 121 في السياق برقم تعريف: 2، وسلسلة خفيفة تشتمل على منطقة متغيرة لسلسلة خفيفة تتكون من سياق أحماض أمينية تمثله مواقع الأحماض الأمينية من 1 إلى 112 في السياق برقم تعريف: 4 ومتقارن يشتمل على الشدفة Fab.
JOP/2020/0002A 2017-07-07 2018-07-06 شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري JOP20200002A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017133698 2017-07-07
PCT/JP2018/025618 WO2019009388A1 (ja) 2017-07-07 2018-07-06 新規な抗ヒトCEACAM5抗体Fabフラグメント

Publications (1)

Publication Number Publication Date
JOP20200002A1 true JOP20200002A1 (ar) 2020-01-06

Family

ID=64950161

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0002A JOP20200002A1 (ar) 2017-07-07 2018-07-06 شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري

Country Status (18)

Country Link
US (1) US11667724B2 (ar)
EP (1) EP3650470A4 (ar)
JP (1) JP7080002B2 (ar)
KR (1) KR102665275B1 (ar)
CN (1) CN110831977B (ar)
AU (1) AU2018296644A1 (ar)
BR (1) BR112020000274A2 (ar)
CA (1) CA3068691A1 (ar)
CO (1) CO2020000517A2 (ar)
IL (1) IL271701A (ar)
JO (1) JOP20200002A1 (ar)
MA (1) MA51029A (ar)
PH (1) PH12020500058A1 (ar)
SG (1) SG11202000069XA (ar)
TW (1) TWI795415B (ar)
UA (1) UA126921C2 (ar)
WO (1) WO2019009388A1 (ar)
ZA (1) ZA202000219B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019010064A2 (pt) 2016-11-18 2019-10-01 Astellas Pharma Inc novo fragmento fab do anticorpo muc1 anti-humano
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
JP7374544B2 (ja) * 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物
JP2022535553A (ja) * 2019-06-04 2022-08-09 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ceacam5モノクローナル抗体、その作製方法およびその使用
JP2023538114A (ja) 2020-08-20 2023-09-06 エー2 バイオセラピューティクス, インコーポレイテッド メソテリン陽性がんを治療するための組成物及び方法
IL300497A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating CEACAM-positive cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1174148A4 (en) 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
AU2001249760B2 (en) 2000-03-30 2005-04-21 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US7273608B2 (en) * 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ599176A (en) 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
CA2665356C (en) 2006-10-04 2017-10-31 Kobenhavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
WO2010050528A1 (ja) 2008-10-28 2010-05-06 塩野義製薬株式会社 抗muc1抗体
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体,包含其的组合物,及其用途
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
IN2012DN01663A (ar) 2009-09-16 2015-06-05 Immunomedics Inc
IN2012DN01981A (ar) 2009-09-24 2015-07-24 Gene Techno Science Co Ltd
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なmuc1抗体
CN101928347B (zh) * 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用
PT3434346T (pt) 2010-07-30 2020-11-26 Medimmune Llc Polipéptidos ou imunoconjugados ativos purificados
CA2827722C (en) 2011-03-02 2020-05-12 Roche Glycart Ag Anti-cea antibodies
JP6164556B2 (ja) 2011-12-01 2017-07-19 国立大学法人 千葉大学 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
KR102408660B1 (ko) * 2012-11-20 2022-06-15 사노피 항-ceacam5 항체 및 이의 용도
ES2673583T3 (es) * 2013-02-28 2018-06-22 National Cancer Center Anticuerpo contra fibrina insoluble
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗il-4/抗il-13之雙特異性抗體調配物
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
KR20160141726A (ko) 2014-04-07 2016-12-09 시애틀 지네틱스, 인크. 항-cd19 항체 및 항체-약물 컨쥬게이트에 대한 안정한 제형
AU2015254257B2 (en) 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
EP3424940A4 (en) 2016-03-01 2019-10-30 National University Corporation Chiba University RADIOMARCED MEDICINE
BR112019010064A2 (pt) 2016-11-18 2019-10-01 Astellas Pharma Inc novo fragmento fab do anticorpo muc1 anti-humano
US10758632B2 (en) 2017-02-06 2020-09-01 City Of Hope NIR-conjugated tumor-specific antibodies and uses thereof
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
EP3689892B1 (en) 2017-09-26 2024-07-17 National University Corporation Chiba University Radioactive drug
BR112020023420A8 (pt) 2018-05-17 2022-06-07 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
JP7374544B2 (ja) 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物
JOP20210180A1 (ar) 2019-01-07 2023-01-30 Astellas Pharma Inc مادة اقتران تشتمل على ربيطة، فاصل، رابط ببتيدي وجزيء حيوي

Also Published As

Publication number Publication date
MA51029A (fr) 2021-03-24
SG11202000069XA (en) 2020-02-27
CN110831977B (zh) 2023-06-09
EP3650470A1 (en) 2020-05-13
BR112020000274A2 (pt) 2020-07-14
CA3068691A1 (en) 2019-01-10
RU2020105654A (ru) 2021-08-09
US20200123270A1 (en) 2020-04-23
KR20200026185A (ko) 2020-03-10
KR102665275B1 (ko) 2024-05-13
EP3650470A4 (en) 2021-03-24
CO2020000517A2 (es) 2020-01-31
UA126921C2 (uk) 2023-02-22
US11667724B2 (en) 2023-06-06
JPWO2019009388A1 (ja) 2020-05-07
TWI795415B (zh) 2023-03-11
AU2018296644A1 (en) 2020-01-23
TW201920273A (zh) 2019-06-01
WO2019009388A1 (ja) 2019-01-10
IL271701A (en) 2020-02-27
ZA202000219B (en) 2021-08-25
JP7080002B2 (ja) 2022-06-03
PH12020500058A1 (en) 2020-09-28
CN110831977A (zh) 2020-02-21
RU2020105654A3 (ar) 2021-10-29

Similar Documents

Publication Publication Date Title
SG11202000069XA (en) Novel anti-human ceacam5 antibody fab fragment
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2020008030A (es) Anticuerpos de glipicano 3 y conjugados de los mismos.
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
PE20161096A1 (es) INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2010004910A (es) Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
NZ594682A (en) Fully human antibodies specific to cadm1
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
PH12018502293A1 (en) Humanized anti-basigin antibodies and the use thereof
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2019004371A (es) Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
PH12016501579A1 (en) Novel anti-presepsin antibody
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1